A single dose of human atMSC that had been genetically modified with adenovirus constructs to overexpress one of two antioxidants, either superoxide dismutase 2 (Sod2) or catalase (Cat), improved hepatic steatosis and systemic inflammation significantly after just 4 weeks. This evidence concerns the gene CAT and Hepatic steatosis.